The Mechanism of cTBS Targeting Dentate Nucleus for DRE

Xijing Hospital50 enrolled

Overview

In our previous cross-over study--the continuous θ burst stimulation (cTBS) targeting cerebellum dentate nucleus of 44 drug-refractory epilepsy (DRE) patients, a significant reduction in seizure frequency was observed. However, the mechanism of this target to reduce seizures is still unknown. This study aims to explore the mechanism of cTBS targeting cerebellum dentate nucleus for DRE, in order to provide theoretical support for this treatment method. A total of 50 patients with DRE will have 2-week cTBS treatment via accurate navigation to bilateral cerebellar dentate nucleus. Participants will be took TMS-EEG, functional magnetic resonance imaging, and diffusion tensor imaging (DTI) pre- and post- treatment. These three examinations will help to analyze the brain functional connectivity and suggest the mechanism of action of this treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Transcranial Magnetic Stimulation Drug Resistant Epilepsy Cerebellum

Interventions

transcranial magnetic stimulationDEVICE

The stimulation intensity will be 80% resting motor threshold (RMT). The theta burst stimulation (cTBS) with a frequency at 50Hz, repeated at 5Hz, are delivered in a duration of 33.2s with the number of stimulation pulses of 600. Two groups of stimulation will be repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. The treatment will last for 2 weeks, with 5 times per week.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Participants aged between 18 and 60, 2. Participants who are in line with the diagnostic criteria for epilepsy and drug-refractory epilepsy (DRE), 3. Participants who have duration of epilepsy ≥ 2 years and seizure frequency ≥ 2 seizures per month, 4. The type and dosage of anti-seizure medications (ASMs) keep unchanged during the experiment, 5. Participants and their families are aware of this study and sign informed consent. Exclusion Criteria: 1. Participants who are unable to cooperate with treatment and examinations, 2. Participants who are in status epilepticus (SE), 3. Participants who are complicated with a serious infection, cerebrovascular disease, malignant tumour, and other nervous system diseases, with serious dysfunction of heart, liver, kidney, and other organs, and with psychiatric disorders, 4. Participants who are pregnant or breastfeeding, 5. Participants have contraindications of TMS and MRI, that is, the presence of metal or implanted devices in the body, such as cardiac pacemaker, deep brain stimulator, etc, 6. Participants who are in other clinical trials, 7. Participants who withdraw informed consent.

Outcomes

Primary Outcomes

TMS evoked potential amplitude change between pre- and post- treatment

TMS-EEG will be recorded pre- and post- treatment by physician and the electroencephalogram (EEG) data will be analyzed with TMS evoked potential by technician, finally, the amplitude change between pre- and post- treatment will be obtained.

Time frame: 8 weeks

functional magnetic resonance images brain functional connection change between pre- and post- treatment

Functional magnetic resonance images (fMRI) will be recorded pre- and post- treatment within 24h. Brain functional connection will be analyzed through fMRI by technician and the change of brain functional connection will be obtained.

Time frame: 2 weeks

diffusion tensor imaging fiber connectivity change between pre- and post- treatment

Diffusion tensor imaging (DTI) will be recorded pre-treatment and post-treatment in three months. DTI data will be analyzed by technician and the change of fiber connectivity change will be obtained.

Time frame: 12 weeks